Abstract The risk of recurrent stroke is likely related to etiology. Therefore it is important to identify which patients are at highest early risk. We evaluated whether selected blood biomarkers may aid in the diagnosis of stroke etiology. We studied consecutive non-lacunar stroke patients between November 2006 and January 2007, and selected undetermined origin strokes. Blood samples were drawn at arrival to test brain natriuretic peptide (BNP), D-dimer, CK-MB, myoglobin, and troponin. Second harmonic transthoracic echocardiography (SHTTE) and ECG-24 h monitoring were also performed within the first 24 h. We evaluated 294 patients with ischemic stroke; 89 had an initial undetermined origin. After a cardiological work-up, 49 were diagnosed as embolic including atrial fibrillation (4), severe aortic arch atheromatosis (24), severe wall abnormalities (12), valve disease (3), dilated cardiomyopathy (1), and patent foramen (5). Higher levels of CK-MB, BNP, and myoglobin were found in patients with embolic source in SHTTE, but only CK-MB[1.5 ng/ml and BNP [64 pg/ml remained as independent predictors: BNP (OR 8.86; CI 95 % 2.79-28.09), CK-MB (OR 6.28; CI 95 % 1.66-23.69). BNP showed specificity of 75 %, sensitivity of 63.4 %, and positive predictive value (PPV) of 75.6 %. CK-MB had specificity of 85 %, sensitivity of 47.9 %, and PPV of 79.3 %. Measuring both biomarkers improves the finding of embolic source, increasing specificity to 95 % and PPV to 88.2 %. High-level CK-MB and BNP during the acute phase of ischemic stroke are associated with an embolic source. Measurement of both biomarkers may improve the diagnosis, guiding the need to perform a heart exploration.
Introduction
Stroke is the third leading cause of death in developed countries and the leading cause of long-term disability [1] . For this reason, identification of the specific cause in every stroke patient has not only important implications in prognosis but also in acute management and in long-term treatments to prevent recurrences.
The risk of recurrent stroke is higher within the first few weeks after a first TIA or stroke and it is likely to be related to the underlying etiology [2] , therefore it is important to obtain more information about which patients are at highest early risk and which investigations are the most urgent to identify such etiology.
Stroke sources include large-artery disease, embolic heart diseases, microangiopathy, and less frequent causes as: arteritis, arterial dissection, venous thrombosis, or hyperviscosity [3, 4] . Unfortunately, about 35 % of all ischemic events remain as cryptogenic, mostly because no potential etiologic mechanism is detected even after performing all available diagnostic tests [5] . Interestingly, the symptoms and neuroimaging findings in many of these patients are suggestive of an embolic source, although no significant alterations are found in cardiologic explorations (24 h-ECG recording and echocardiography). Therefore, although anticoagulants might be the best secondary prevention strategy in many of those cases, alternative tests are lacking to support the selection of that treatment and more conservative regimes (antiplatelets) are usually prescribed.
Some authors have stated the usefulness of biomarkers in this aspect, not only as a possible tool to help us in stroke diagnose [6, 7] but also in diagnosing the different etiological subtypes of an ischemic stroke [8, 9] . As the pathologic substrate is so different among stroke subtypes, the embolic source might be associated with specific biological markers. Among these biomarkers, BNP [10] is associated with cardiac disorders, and its use is increasing in clinical practice. Other authors have studied the role of hemostatic markers, platelet aggregation factors, or D-dimer associated with ischemic strokes [11] [12] [13] .
Therefore, our aim was to evaluate the usefulness of some of these biomarkers in identifying an embolic source within the hyperacute stroke among those patients with an unknown etiology.
Methods
All consecutive acute ischemic stroke patients admitted at our stroke unit from November 2006 and January 2007 were evaluated, including TIA (a total of 274 patients). All etiologies were classified following TOAST criteria [3] after an initial etiological work-up that included transcranial and carotid duplex sonography and ECG-monitoring.
An experienced neurologist performed a transcranial and carotid duplex sonography to rule out vessel occlusions or stenoses in intra/extracranial arteries that would indicate an atherothrombotic stroke. We considered a large artery disease if stenoses were [50 %.
Those patients with known heart disease, such as atrial fibrillation (AF), valve disease, prosthetic valve replacement, severe dilated cardiomyopathy, or recent acute myocardial infarct, were considered to have a cardioembolic stroke, and therefore they were excluded from our evaluation.
All of these patients were recorded with ECG monitoring within 24 h, and the detection of a previously unknown AF was considered the most important finding for these investigations, and the cause of the index ischemic stroke.
In summary, we analyzed the patients with an initial etiological diagnose of undetermined origin, i.e., a normal transcranial/carotid sonography and sinus rhythm.
In those patients, a second harmonic transthoracic echocardiography (SHTTE) was performed within the first 24 h after the stroke onset (mean time of performance 14 ± 9 h). Specific attention was focused on findings that might be potential embolic sources: firstly, the presence of left atrial or left ventricular thrombus/mass, secondly, the detection of any structural abnormality considered as a potential embolic source: atrial septal abnormality, left atrial spontaneous echocardiography contrast, left atrial mass, mitral or aortic valve stenosis (valve disease), abnormal segmental wall motion (akynesia/dyskynesia) and a poor left ventricular function (ejection fraction \40 %); finally, the aortic arch was studied, defining the presence of a significant aortic arch atheroma as the visualization of mobile plaques C4 mm thick and complex morphology within the aortic arch according to previous studies [14] . After cardiac explorations, we defined any finding as embolic group (cardiac and aortic arch). All explorations were performed by the same trained cardiologist using a Vivid 7 ultrasound system (GE Healthcare).
Furthermore, blood samples were drawn at the stroke unit arrival to test a panel of biomarkers in that group of patients, including brain natriuretic peptide (BNP), D-dimer (DD), CK-MB, myoglobin (MYO), and troponin. BNP was measured in pg/ml, and BNP, DD, CK-MB, and MYO were measured in ng/ml. Blood sampling for biomarkers was performed within 24 h of stroke onset and before any treatment was administered to avoid drug-biomarker interferences. Blood was drawn into EDTA tubes and centrifuged at 3,000 rpm for 15 min, and plasma was frozen at -80°C until analysis. All biomarkers were assayed by using Triage Ò Profiler S.O.B TM Panel (Inverness). The study protocol was approved by the local ethics committee and all patients or relatives gave their written, informed consent.
Statistical analyses
Descriptive and frequency statistical analyses were obtained and comparisons were performed with SPSS for Windows, version 15.0. Biomarkers were not normally distributed (Q-Q plot). Statistical significance for intergroup differences was assessed by Pearson's v 2 for categorical variables and Student's t test or Mann-Whitney U test for continuous variables. To calculate the sensitivity and specificity for biomarker cut-off values to predict an embolic etiology, a receiver operator characteristic (ROC) curve was configured. Variables associated in the univariate analysis were entered into a forward stepwise logisticregression model to identify variables independently associated with cardioembolic etiology (odds ratios [OR] with their 95 % CIs are given).
The Hosmer and Lemeshow test was used to assess the goodness-of-fit of the model. The accuracy of risk prediction was assessed with a calibration curve.
Model discrimination was assessed by the area under a ROC curve. An area of 0.5 indicates no discrimination, and an area of 1.0 indicates perfect discrimination.
A probability value \0.05 was considered statistically significant.
Results
After an initial evaluation of all ischemic stroke patients admitted at our stroke unit, we selected a total of 89 patients with a non-lacunar ischemic stroke without an atherothrombotic etiology or known heart disease, and a sinus rhythm. Mean age was 71.32 ± 13 years old, and 53.9 % were men. Hypertension was present in most of them (66.3 %), and 22.5 % had suffered from a previous stroke. The rest of the risk factor profile and the clinic severity are shown in Table 1 .
After an early cardiological work-up, 49 patients were diagnosed as having an embolic stroke, and 40 remained as cryptogenic stroke. An AF during the ECG monitoring was detected in four patients, and 45 patients showed embolic abnormalities in the emergency department echocardiography. The most frequent findings were the presence of a severe aortic atheromatosis (mobile plaque or thicker than 4 mm) in 24 patients and severe dyskynesia/akynesia of left ventricular wall in 12 patients. Other echocardiographic findings included the presence of an important patent foramen ovale (PFO) with aneurysm of atrial septum (ASA) in five patients, valvular disease in three patients, and dilated cardiomyopathy in one patient. No patient had signs or symptoms of congestive heart failure before the stroke.
The distribution of risk factors and clinical features among these two different etiologic subtypes is shown in Table 2 . We did not find any differences between demographics or risk factor profiles in these two groups; however, regarding biomarker distribution, we observed significant higher plasma levels in the group of patients with The ROC curves obtained to select the cut-off values that offered the best sensitivity and specificity for differentiating embolic stroke from undetermined etiology identified the following values: BNP [64 pg/ml, MYO [1.40 ng/ml, and CK-MB [1.5 ng/ml, which were used for inclusion in the multivariate analysis.
Brain natriuretic peptide[64 pg/ml showed a specificity of 75 %, a sensitivity of 63.4 %, a positive predictive value (PPV) of 75.6 %, and a negative predictive value (NPV) of 75.6 %; MYO[1.40 ng/ml showed a specificity of 90.2 %, a sensitivity of 37.5 %, a PPV of 85.7 % and a NPV of 55.2 % and CK-MB [1.5 ng/ml had a specificity of 85 %, a sensitivity of 47.9 %, a PPV of 79.3 %, and a NPV of 79.3 %.
Brain natriuretic peptide (OR 8.06; CI 95 % 2.34-27.72), CK-MB (OR 6.52; CI 95 % 1.44-29.50) and previous stroke (OR 5.34; CI 95 % 1.14-24.97) appeared to be independent predictors of an embolic source after performing a logistic regression adjusted by risk factors, age, gender, the presence of heart disease obtained by history and stroke severity (see Table 3 ).
There was a good adjustment of the model to the data (Hosmer and Lemeshow statistic, p = 0.15). A calibration curve revealed that the model was well adjusted (see Fig. 2 ).
The discriminating ability of the model was very good, as shown by the ROC curve, with an area under the curve of 0.837 (95 % CI, 0.756-0.919; see Fig. 3 ).
Measuring both biomarkers might improve the etiologic diagnosis of embolic stroke (see Fig. 2 ). In fact, the number of cases with a diagnosis of embolic stroke increased when both CK-MB and BNP levels were high (p \ 0.0001; difference between high CKMB/high BNP and low CKMB/low BNP , Fig. 4) ; when we consider both values above the cut-off, the specificity and PPV rise (specificity 95 %, PPV 88.2 %); in this case, the sensitivity and NPV are lower (sensitivity 31.2 % and NPV 53.5 %).
Discussion
The results of our study are in accordance with previous reports stating the usefulness of blood biomarkers in diagnosing the different etiological subtypes of ischemic stroke [8, 9, 11, 12] ; in this case, some of these biomarkers may help us to select which patients are more likely to have embolic features after the cardiological explorations within the first hours after the stroke. When designing the study, we selected some biomarkers used for cardioembolic disorders or previously related to cardioembolic stroke; among them BNP, which is a potential marker of heart failure and myocardial ischemia. Fig. 4 Relation between BNP and CK-MB levels with embolic stroke. The differences when comparing the high-level groups with the low-level group were statistically significant. *p = 0.011, difference between high CKMB/low BNP and low CKMB/low BNP. **p = 0.002, difference between low CKMB/high BNP and low CKMB/low BNP. ***p \ 0.001, difference between high CKMB/ high BNP and low CKMB/low BNP BNP is secreted by the myocardium and the left atrium is its main source [15] [16] [17] . Elevated levels may reflect increased cardiac chamber wall stress and/or intrinsic atrial disease [18] , and it has been described in patients with AF and clinical evidence of thromboembolism [19] or when systolic or diastolic dysfunction exists [20] . Based on these data, some reports have pointed out BNP as a marker of cardioembolic origin in stroke patients [9, 15, 21] and more recently BNP has been defined as a predictor of delayed AF in stroke patients [22] , and also as a marker associated with atrial thrombi in stroke patients [23] . Therefore, among our stroke patients, a high BNP level seems to be a good indicator of an appropriate condition to develop thrombi. There are other markers from the natriuretic peptide family available, such as N-terminal pro b-type natriuretic peptide (Nt-proBNP) or atrial natriuretic peptide (ANP)/ mid regional proANP (MRproANP) that have been associated with cardioembolic stroke, however, we chose BNP for its wider use in cardiology to assess different aspects of heart disease.
Markers of myocardial lesion as CK-MB, myoglobin, and troponin and have also been described as markers of non-ischemic lesions and as factors of bad prognosis in ischemic stroke [24] [25] [26] [27] [28] .
In our study, although higher levels of all these biomarkers were found in embolic strokes, only BNP and CK-MB remained independently related to embolic abnormalities. This association was found both in patients with AF in 24 h-ECG recording and in patients with sinusal rhythm carrying other embolic findings. The impact of adding these biomarkers to clinical information might lead us to perform a better selection of patients to undergo an emergent cardiologic study.
Although BNP was previously associated with embolic stroke, there are no data associated with stroke etiology regarding CK-MB levels; in all of our patients, there is a lack of evidence of an acute coronary syndrome (clinical and ECG), however, small low-grade myocardial necrosis suggestive of myocytolysis may be present in patients with abnormal segmental left ventricular wall motion or a possible association in patients with severe aortic atheromatosis (the most frequent finding in SHTTE). Nevertheless, we could not correlate directly these findings with higher levels of CK-MB due to the small total number of patients.
D-dimer has been described as an independent predictor of cardioembolic stroke [12] . Thrombi in the cardiac chambers are mainly due to blood stasis producing a fibrinrich clot, and this would lead to an enhancement of coagulation activity, and high levels of D-dimer [28] .
We found no statistical association with D-dimer and embolic source group. These results may be due to the selection of patients; there are patients with an embolic source in the aortic arch within the ''embolic stroke'' group in which clots have a predominant platelet component, compared to clots of a cardioembolic origin with a predominant fibrin component. Therefore, patients with an aorto-embolic disorder would not have important activation of fibrinolytic mechanisms, and their D-dimer levels would be normal, decreasing the differences between undetermined and embolic stroke groups. Similar explanations may be the cause of lack of differences in myoglobin levels.
Most interestingly, many of the abnormalities in the SHTTE are found in the aortic arch, and no association has been described between some of these biomarkers and atheromatosis in aortic arch (AAA), except for D-Dimer. Some authors [29] have pointed out the possibility of an enhanced coagulation activity in patients with AAA, however, these changes seemed to occur only when spontaneous echocontrast is found in the study. None of our patients showed aortic spontaneous echocontrast.
The association between an embolic source and BNP/ CK-MB levels is stronger combining both biomarkers. In fact, when the two exceed the cut-off values, the etiological diagnosis will be embolic in 88.2 % (see Fig. 2 ). In this case, the sensitivity is low; however, a high specificity and PPVs allow a better selection of patients to increase the efficiency of the echocardiography within the acute phase. In summary, in a stroke patient, the determination of biomarkers jointly with sonographic and clinical parameters yielded the most accurate prediction to find an embolic abnormality in the cardiac explorations, and may help us to select patients with a previous unknown source for a ''prioritized'' emergent study.
One important feature of our study is the early performance of the cardiac explorations, i.e., within the first 24 h after the stroke onset; some authors [30] have described that embolic clots are dissolved within the first 72 h, and may be undetectable in the embolic source after this period of time. In this case, we assumed that the association would be higher within the first hours.
Our study has some limitations; first of all, the sample size and the lack of other findings considered as embolic sources. Some cardioembolic pathologies such as atrial myxoma, endocarditis (infective or not infective), or the presence of spontaneous echocontrast were not detected due to the low rate of their finding in ischemic stroke. This low or no detection of these pathologies had already been reported previously performing a TTE [31] . Regarding the presence of intracavitary thrombi, their finding was lower than expected. Previous studies [31] [32] [33] [34] have reported similar results (0.5-2 %) performing TTE in a variable time after the stroke onset. Our results indicate that although the exploration is performed early, it may be late for thrombi detection inside the cardiac chambers. Regarding the finding of septal abnormalities, we considered as likely embolic those patients with a PFO associated with ASA although early evaluation did not show deep venous thrombosis. Another limitation is that transesophageal echocardiography (TEE) was not performed to confirm or increase the rate of findings. In acute ischemic stroke patients, we have considered SHTTE as the best therapeutic option to image cardiac structures because it is a non-invasive technique, and since the introduction of second harmonic imaging in TTE techniques, the visualization of aortic arch and left auricular has improved considerably, and some authors [35] have reported the higher value of SHTTE in the detection of alterations in these structures.
Regarding the selection of patients, we did not include other etiologic subtypes of stroke although some of them may have significant cardiac findings. The scales of etiologic diagnosis of stroke have certain limitations and recent versions have accepted the fact that there are shared phenotypes [36] (which would not be identified here). It may also be interesting to know the role of these biomarkers in double etiologies. Another reason not to include the results of atherothrombotic or lacunar strokes is because we wanted to focus on the group of patients with more difficulties to diagnose an etiology in our clinical practice during the hyperacute phase. Furthermore, the comparison between stroke subtypes had been evaluated previously showing its usefulness [9] .
It is true that an early evaluation from a cardiological point of view will improve the detection of a heart or aortic embolic source, but these techniques are not available (TTE/TEE) during the hyperacute phase of stroke in most hospitals, mainly in smaller hospitals. On the other hand, many cryptogenic strokes are likely to be comprised of embolic strokes not identified. For example, paroxysmal AF can be found in patients initially diagnosed as cryptogenic. Our data suggest that the analysis of these biomarkers should prioritize performing examinations to detect cardiac embolic sources in some patients. This does not mean that in patients with normal levels, the embolic source is ruled out, but it is less likely that any abnormalities suggestive of embolism are found.
It might be very interesting to evaluate after a complete etiological work-up, those patients with higher levels suggesting a cardio-embolic source which was not captured before in future studies, including other factors such neuroimaging (embolic patterns) and recurrence.
With regard to biomarker measurement, variability exists among different assays used to determine their levels [37] , and these assays should be compared and validated in the future if any of them are to be used in clinical practice in stroke.
Conclusions
High levels of some blood biomarkers (CK-MB and BNP) during the acute phase of an ischemic stroke are associated with the presence of an embolic lesion in the cardiac explorations. The analysis of these biomarkers may help us to improve the diagnosis of an embolic source of stroke during the acute phase, guiding the need to perform an early cardiac exploration and increasing the yield of these tests. More studies are needed to validate and select which panel of biomarkers is more suitable for detecting an embolic source.
